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Purpose or Objective: A new entity of patients with 
recurrent prostate cancer limited to a small number of active 
metastatic lesions is having growing interest: the 
oligometastatic patients. Patients with oligometastatic 
disease could eventually be managed by treating all the 
active lesions with local therapy, i.e. either surgery or 
ablative stereotactic body radiotherapy. This study aims to 
assess the impact of [18F]Choline ([18F]FMCH) PET/CT and 
the use stereotactic body radiotherapy (SBRT) in patients 
(pts) with oligometastatic prostate cancer (PCa). 
 
Material and Methods: Twenty-nine pts with oligometastatic 
PCa (≤3 synchronous active lesions detected with 
[18F]FMCHPET/CT) were treated with repeated salvage SBRT 
until disease progression (development of > three active 
synchronous metastases). Primary endpoint was systemic 
therapy-free survival measured from the baseline 
[18F]FMCHPET/CT. 
 
Results: A total of 45 lesions were treated with SBRT. After a 
median follow-up of 11.5 months (range 3-40 months), 20 pts 
were still in the study and did not receive any systemic 
therapy. Nine pts started systemic therapy, and the median 
time of the primary endpoint was 39.7 months (CI 12.20-
62.14 months). No grade 3 or 4 toxicity was recorded. 
 
Conclusion: Repeated salvage [18F]FMCHPET/CT-guided 
SBRT is well tolerated and could defer the beginning of 
systemic therapy in selected patients with oligometastatic 
PCa. 
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Purpose or Objective: 5-fraction SBRT using CyberKnife is a 
well-established safe alternative treatment for selected low-
risk (LR) and intermediate-risk (IR) prostate cancer.  
The aim of this study is to determine prospectively the 
morbidity (CTCAE) and QOL (auto-administered IPSS) of an 8-
fraction scheme for high-risk (HR), IR and LR using 
tomotherapy. 
 
Material and Methods: Exclusion criteria were T3b-4, GS 9-
10, PSA ≥50, IPSS ≥20.  
Since 2012 eighty-two patients were treated: 41 HR (23/41 
with GS ≥8 or PSA >20 or T3a, and 18/41 with ≥2 
intermediate risk factors), 17 IR (GS 7 or PSA 10-20 or T2b-c), 
and 24 LR.  
57/82 patients received 6-month hormonal therapy (HT).  
8 fractions of 5.65 Gy for HR-IR, and 5.48 Gy for LR patients 
were delivered every other day over about 2.5 weeks. EQD2 
is 92.3 Gy (HR, IR) or 87.4 Gy (LR) for prostate cancer (a/b 
1.5), and 78.2 or 74.3 Gy for late-responding tissues (a/b 3), 
respectively. 
 
Results: Median follow-up was 13.7 months (0.3-40.1). 
No acute/late grade ≥3 events were observed. Late GU or GI 
grade 2 toxicities were far bellow 10% (see Table). We 
observed a slight urinary flare at 18 months. 
 
  
During/following 
SBRT (N=81) 
1 
month 
(N=80) 
6 
months 
(N=66) 
12 
months 
(N=50) 
18 
months 
(N=35) 
24 
months 
(N=27) 
GU 
toxicity 
Grade 
1 41 50.6% 
17 
21.2% 
11 
16.7% 9 18% 3 8.6% 2 7.4% 
 
Grade 
2 17 21% 
3 
3.8% 0 0% 0 0% 2 5.7% 0 0% 
GI 
toxicity 
Grade 
1 26 32.1% 8 10% 6 9.1% 9 18% 7 20% 1 3.7% 
 
Grade 
2 10 12.4% 0 0% 1 1.5% 1 2% 1 2.9% 2 7.4% 
GU / GI 
toxicity 
Grade 
3+ 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 
 
IPSS scores (Q1-7) and patient satisfaction (Q8) returned to 
baseline at 6 months (p=0.21), after they significantly 
worsened at the last fraction (p=0.00), especially the IPSS-
obstructive component (see Figure). 
 
 
 
Without HT, PSA nadir has not been reached yet. Mean value 
at 24 months was 0.66 ng/mL.  
With HT, PSA nadir was reached between 1-6 months and 
then raised up to 0.37 ng/mL average at 18 months (mean 
testosterone 291 ng/dL), to remain steady afterwards. 
No biochemical (nadir+2) /clinical failure was found. One 
unrelated cancer/treatment death occurred during SBRT. 
 
Conclusion: To our knowledge this is the first communication 
of SBRT using helical tomotherapy for localized prostate 
cancer.  
The 8-fraction scheme is being well tolerated, with no 
moderate-severe toxicity, suggesting that this approach is 
safe.  
Longer follow-up is needed to find out whether the delivery 
of equivalent doses near the plateau of the dose-response 
curve (>90 Gy) results in better tumour control in this cohort 
of patients (mostly HR and IR tumours). 
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